Palmitoylethanolamide (PEA) is an endogenous lipid modulator in animals and humans,
and has been evaluated since the 1970s as an anti-inflammatory and analgesic drug in …

The endocannabinoid, arachidonoylethanolamide (AEA), and the peroxisome proliferator‐
activated receptor (PPAR)‐α ligand, oleylethanolamide (OEA) produce opposite effects on …

Identifying points of control in inflammation is essential to discovering safe and effective
antiinflammatory medicines. Palmitoylethanolamide (PEA) is a naturally occurring lipid …

Objective. To assess the efficacy and safety of palmitoylethanolamide (PEA), an
endogenous fatty acid amide belonging to the N-acylethanolamines family, in reducing pain …

Palmitoylethanolamide (PEA), an endogenous lipid mediator, is emerging as a promising
pharmacological agent in multiple neurodegenerative disorders for its anti-inflammatory and …

Chronic pain is a major source of morbidity for which there are limited effective treatments.
Palmitoylethanolamide (PEA), a naturally occurring fatty acid amide, has demonstrated utility …

N-acylethanolamines (NAEs) comprise a family of bioactive lipid molecules present in
animal and plant tissues, with N-palmitoylethanolamine (PEA) having received much …

Endocannabinoids like 2-arachidonoylglycerol strongly modulate the complex machinery of
secondary neuronal damage and are shown to improve neuronal survival after excitotoxic …

Parkinson's disease (PD) is a disorder resulted by degeneration of dopaminergic neurons.
To counteract the neuroinflammation and oxidative stress of PD, we decided to test a new …

Alzheimer's disease (AD) is the most common neurodegenerative disorder. Its
neuropathological hallmarks include deposition of beta amyloid (Aβ) fibrils in senile …